WO2009083185A3 - Compositions and methods for prophylaxis and treatment of cellular degenerative ophthalmic disorders - Google Patents

Compositions and methods for prophylaxis and treatment of cellular degenerative ophthalmic disorders Download PDF

Info

Publication number
WO2009083185A3
WO2009083185A3 PCT/EP2008/010922 EP2008010922W WO2009083185A3 WO 2009083185 A3 WO2009083185 A3 WO 2009083185A3 EP 2008010922 W EP2008010922 W EP 2008010922W WO 2009083185 A3 WO2009083185 A3 WO 2009083185A3
Authority
WO
WIPO (PCT)
Prior art keywords
prophylaxis
treatment
compositions
methods
cellular degenerative
Prior art date
Application number
PCT/EP2008/010922
Other languages
French (fr)
Other versions
WO2009083185A2 (en
Inventor
Anne Galy
Naomi Berdugo
Original Assignee
Fovea Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fovea Pharmaceuticals Sa filed Critical Fovea Pharmaceuticals Sa
Publication of WO2009083185A2 publication Critical patent/WO2009083185A2/en
Publication of WO2009083185A3 publication Critical patent/WO2009083185A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present application relates to novel therapeutic strategies for cellular degenerative ophthalmic diseases, and more specifically diseases associated with photoreceptors degeneration such as age-related macular degeneration, retinitis pigmentosa, macular and retinal edema and uveitis. The invention relates to a novel use of Unc51-Like Kinase modulator, and more specifically of Unc51-Like Kinase inhibitors. The compounds of the invention are useful for the preparation of pharmaceutical compositions for prophylaxis and treatment of cellular degenerative ophthalmic diseases.
PCT/EP2008/010922 2007-12-28 2008-12-19 Compositions and methods for prophylaxis and treatment of cellular degenerative ophthalmic disorders WO2009083185A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07360064 2007-12-28
EP07360064.5 2007-12-28

Publications (2)

Publication Number Publication Date
WO2009083185A2 WO2009083185A2 (en) 2009-07-09
WO2009083185A3 true WO2009083185A3 (en) 2010-01-14

Family

ID=40824763

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/010922 WO2009083185A2 (en) 2007-12-28 2008-12-19 Compositions and methods for prophylaxis and treatment of cellular degenerative ophthalmic disorders

Country Status (1)

Country Link
WO (1) WO2009083185A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2486130A1 (en) * 2009-10-06 2012-08-15 Tallinn University Of Technology Inhibition or activation of serine/threonine ulk3 kinase activity
US10266549B2 (en) 2014-08-25 2019-04-23 Salk Institute For Biological Studies ULK1 inhibitors and methods using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079478A2 (en) * 2001-03-30 2002-10-10 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Modification of organelle metabolism by a composition comprising unc-51-like kinases, roma1, or 2tm polypeptides and uses thereof for the preration of a medicament for the treatment disorders
WO2005101013A2 (en) * 2004-04-15 2005-10-27 Reglia Ab Materials and methods for screening modulators of neural regneration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079478A2 (en) * 2001-03-30 2002-10-10 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Modification of organelle metabolism by a composition comprising unc-51-like kinases, roma1, or 2tm polypeptides and uses thereof for the preration of a medicament for the treatment disorders
WO2005101013A2 (en) * 2004-04-15 2005-10-27 Reglia Ab Materials and methods for screening modulators of neural regneration

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REX TONIA S: "Rescue of sight by gene therapy - closer than it may appear.", OPHTHALMIC GENETICS SEP 2007, vol. 28, no. 3, September 2007 (2007-09-01), pages 127 - 133, XP009125523, ISSN: 1381-6810 *

Also Published As

Publication number Publication date
WO2009083185A2 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
PH12015501208A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
WO2009005794A3 (en) Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
MY155320A (en) Alkoxy compounds for disease treatment
WO2013061205A8 (en) (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
WO2010066684A3 (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
WO2009155121A3 (en) Inhibitors of pi3 kinase
GEP20146101B (en) Pyridine and pyrazine derivatives as protein kinase modulators
WO2012009009A3 (en) Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
WO2009036996A3 (en) Small molecule bradykinin b1 receptor antagonists
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
WO2010121576A3 (en) Novel 7-deazapurine nucleosides for therapeutic uses
WO2007098122A3 (en) Methods for the treatment of macular degeneration and related eye conditions
MY153738A (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders.
WO2012048129A3 (en) Inhibitors of polo-like kinase
MX2021010888A (en) Heteroaromatic and heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders.
MX337849B (en) Compositions and methods for inhibition of the jak pathway.
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
WO2008010061A3 (en) 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
MX2010002900A (en) Tricyclic heterocyclic derivatives.
WO2009109501A3 (en) Ocular pharmaceutical compositions
WO2008048675A3 (en) Treatment for age-related macular degeneration and other diseases of the eye

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08866601

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08866601

Country of ref document: EP

Kind code of ref document: A2